Lindblad Expeditions Shares Drop Post Mixed Q2 Results
Lindblad Expeditions Holdings Inc (NASDAQ:LIND) reported second-quarter FY22 sales of $90.90 million versus $15.3 million last year, beating the analyst consensus of…
Krystal Biotech Gets FDA Nod For Initial-Stage Lung Infection Study
The United States Food and Drug Administration (FDA) has accepted Krystal Biotech’ (NASDAQ: KRYS) Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis (CF).
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
Gainers
MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
Gainers
Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings (CCNB).
Chevron, Amazon And Some Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones jumping more than 300 points. Here is the list of some big stocks moving higher in the previous session.
Biotech Investors: August’s Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.
Week’s Biggest EV Stories: Manchin-Schumer Lift To Industry, Apple Brisk With Car Patent Filings, Ford Delivers In Q2, GM’s Green Bond Sales, Rivian’s Struggles And More
Electric vehicle stocks had a mixed close in the week ending July 29, although market leader Tesla, Inc. (NASDAQ: TSLA) managed to build on its gains. Chinese EV stocks and some pure-play U.S. startups came under selling pressure despite a positive development on EV tax credits.
2 Stocks To Watch As House Passes ‘Assault Weapons Ban’ Bill: What’s Next?
The U.S. House of Representatives late Friday passed a bill to reinstate the “Assault Weapons Ban,” nearly two decades after such a prohibition ended.
Recap Of Friday’s Biotech Catalysts – End of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE…
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older.